Compass Pathways plc (NASDAQ: CMPS) announced a grant program for U.S. organizations to develop training content for healthcare providers who would deliver its investigational COMP360 psilocybin treatment if approved by regulators.

The biotechnology company plans to award grants to up to three organizations to support development of foundational psychedelic and COMP360-specific training materials. Applications will be accepted from April 14 through May 14, 2026, according to the company's statement.

The grant program aims to prepare healthcare providers for the potential commercial launch of COMP360 for treatment-resistant depression. COMP360 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.

"As we prepare for the potential commercial launch of COMP360 for treatment-resistant depression, our priority is ensuring that healthcare providers are trained, confident, and ready to deliver COMP360 treatment responsibly where eligible patients may receive care," said Dr. Steve Levine, Chief Patient Officer at Compass Pathways.

The application process consists of two stages over approximately three months. Applicants must demonstrate experience in psychedelics training design, delivery, and governance, along with ability to scale, focus on access and inclusion, and regulatory alignment.

Organizations selected in the first stage will receive notification by late May, with final decisions expected by early July. The company stated that many training organizations already exist and have trained thousands of healthcare providers in psychedelic care.

Compass Pathways is developing COMP360 as a synthetic psilocybin treatment and is headquartered in London with offices in New York.